208 related articles for article (PubMed ID: 22253776)
21. Non-Human Primate Models of Tuberculosis.
Peña JC; Ho WZ
Microbiol Spectr; 2016 Aug; 4(4):. PubMed ID: 27726820
[TBL] [Abstract][Full Text] [Related]
22. Animal Models of Tuberculosis: An Overview.
Williams A; Orme IM
Microbiol Spectr; 2016 Aug; 4(4):. PubMed ID: 27726810
[TBL] [Abstract][Full Text] [Related]
23. The ΔfbpA attenuated candidate vaccine from Mycobacterium tuberculosis, H37Rv primes for a stronger T-bet dependent Th1 immunity in mice.
Roche CM; Smith A; Lindsey DR; Meher A; Schluns K; Arora A; Armitige LY; Jagannath C
Tuberculosis (Edinb); 2011 Dec; 91 Suppl 1():S96-104. PubMed ID: 22082615
[TBL] [Abstract][Full Text] [Related]
24. Importance of confirming data on the in vivo efficacy of novel antibacterial drug regimens against various strains of Mycobacterium tuberculosis.
De Groote MA; Gruppo V; Woolhiser LK; Orme IM; Gilliland JC; Lenaerts AJ
Antimicrob Agents Chemother; 2012 Feb; 56(2):731-8. PubMed ID: 22143517
[TBL] [Abstract][Full Text] [Related]
25. Application of Fluorescent Protein Expressing Strains to Evaluation of Anti-Tuberculosis Therapeutic Efficacy In Vitro and In Vivo.
Kong Y; Yang D; Cirillo SL; Li S; Akin A; Francis KP; Maloney T; Cirillo JD
PLoS One; 2016; 11(3):e0149972. PubMed ID: 26934495
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity and protection induced by Mycobacterium tuberculosis mce-2 and mce-3 mutants in a Balb/c mouse model of progressive pulmonary tuberculosis.
Aguilar LD; Infante E; Bianco MV; Cataldi A; Bigi F; Pando RH
Vaccine; 2006 Mar; 24(13):2333-42. PubMed ID: 16388878
[TBL] [Abstract][Full Text] [Related]
27. Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis.
Nikonenko BV; Samala R; Einck L; Nacy CA
Antimicrob Agents Chemother; 2004 Dec; 48(12):4550-5. PubMed ID: 15561824
[TBL] [Abstract][Full Text] [Related]
28. [A study of the protective effect of the DNA vaccine encoding tubercle antigen 85B with MPT64 in mice challenged with Mycobacterium tuberculosis].
Luo XD; Zhu DY; Chen Q; Jiang Y; Jiang S; Yang C
Zhonghua Jie He He Hu Xi Za Zhi; 2004 Sep; 27(9):611-6. PubMed ID: 15498274
[TBL] [Abstract][Full Text] [Related]
29. Activity of ketoconazole against Mycobacterium tuberculosis in vitro and in the mouse model.
Byrne ST; Denkin SM; Gu P; Nuermberger E; Zhang Y
J Med Microbiol; 2007 Aug; 56(Pt 8):1047-1051. PubMed ID: 17644711
[TBL] [Abstract][Full Text] [Related]
30. The immunogenicity and protective efficacy of Mtb8.4/hIL-12 chimeric gene vaccine.
Li H; Li R; Zhong S; Ren H; Zou Y; Chen X; Shi X; Wang M; Long H; Luo Y
Vaccine; 2006 Feb; 24(9):1315-23. PubMed ID: 16219397
[TBL] [Abstract][Full Text] [Related]
31. Simple and rapid method to determine antimycobacterial potency of compounds by using autoluminescent Mycobacterium tuberculosis.
Sharma S; Gelman E; Narayan C; Bhattacharjee D; Achar V; Humnabadkar V; Balasubramanian V; Ramachandran V; Dhar N; Dinesh N
Antimicrob Agents Chemother; 2014 Oct; 58(10):5801-8. PubMed ID: 25049243
[TBL] [Abstract][Full Text] [Related]
32. Development of new vaccines and drugs for TB: limitations and potential strategic errors.
Orme IM
Future Microbiol; 2011 Feb; 6(2):161-77. PubMed ID: 21366417
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE
Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361
[TBL] [Abstract][Full Text] [Related]
34.
Shetye GS; Choi KB; Kim CY; Franzblau SG; Cho S
Antimicrob Agents Chemother; 2021 Jul; 65(8):e0028221. PubMed ID: 34097493
[TBL] [Abstract][Full Text] [Related]
35. An adult zebrafish model for preclinical tuberculosis vaccine development.
Oksanen KE; Halfpenny NJ; Sherwood E; Harjula SK; Hammarén MM; Ahava MJ; Pajula ET; Lahtinen MJ; Parikka M; Rämet M
Vaccine; 2013 Oct; 31(45):5202-9. PubMed ID: 24055305
[TBL] [Abstract][Full Text] [Related]
36. [Protective efficacy of DNA vaccines encoding mycobacterium tuberculosis Ag85B protein].
Fan XL; Xu ZK; Li Y; Li BH; Xue Y; Bai YL; Bai GC; Jia XZ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2003 Jan; 19(1):90-2. PubMed ID: 15132919
[TBL] [Abstract][Full Text] [Related]
37. Resazurin reduction assays for screening of anti-tubercular compounds against dormant and actively growing Mycobacterium tuberculosis, Mycobacterium bovis BCG and Mycobacterium smegmatis.
Taneja NK; Tyagi JS
J Antimicrob Chemother; 2007 Aug; 60(2):288-93. PubMed ID: 17586560
[TBL] [Abstract][Full Text] [Related]
38. New drugs and vaccines for drug-resistant Mycobacterium tuberculosis infections.
Dover LG; Bhatt A; Bhowruth V; Willcox BE; Besra GS
Expert Rev Vaccines; 2008 May; 7(4):481-97. PubMed ID: 18444894
[TBL] [Abstract][Full Text] [Related]
39. Rapid, Semiquantitative Assay To Discriminate among Compounds with Activity against Replicating or Nonreplicating Mycobacterium tuberculosis.
Gold B; Roberts J; Ling Y; Quezada LL; Glasheen J; Ballinger E; Somersan-Karakaya S; Warrier T; Warren JD; Nathan C
Antimicrob Agents Chemother; 2015 Oct; 59(10):6521-38. PubMed ID: 26239979
[TBL] [Abstract][Full Text] [Related]
40. Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis.
Ahmad Z; Tyagi S; Minkowsk A; Almeida D; Nuermberger EL; Peck KM; Welch JT; Baughn AS; Jacobs WR; Grosset JH
Indian J Med Res; 2012 Nov; 136(5):808-14. PubMed ID: 23287128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
